🇺🇸 FDA
Patent

US 11845937

RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use

granted A61KA61K47/64A61P

Quick answer

US patent 11845937 (RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use) held by Arrowhead Pharmaceuticals, Inc. expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K47/64, A61P, A61P21/00